Published in Thromb Res on April 22, 2015
Factor XIa inhibitors: A review of the patent literature. Expert Opin Ther Pat (2016) 0.76
Allosteric Inhibition of Factor XIIIa. Non-Saccharide Glycosaminoglycan Mimetics, but Not Glycosaminoglycans, Exhibit Promising Inhibition Profile. PLoS One (2016) 0.76
A molecular dynamics-based algorithm for evaluating the glycosaminoglycan mimicking potential of synthetic, homogenous, sulfated small molecules. PLoS One (2017) 0.75
Medically-induced hemophilia C to treat thrombosis. Thromb Res (2015) 0.75
Mechanistic and therapeutic overview of glycosaminoglycans: the unsung heroes of biomolecular signaling. Glycoconj J (2015) 0.75
Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med (2014) 4.58
Polyphosphate exerts differential effects on blood clotting, depending on polymer size. Blood (2010) 2.66
High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med (2000) 2.39
Factor XI contributes to thrombin generation in the absence of factor XII. Blood (2009) 2.31
Polyphosphate is a cofactor for the activation of factor XI by thrombin. Blood (2011) 2.24
Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association. Circulation (2001) 2.01
Human blood coagulation factor XI. Purification, properties, and mechanism of activation by activated factor XII. J Biol Chem (1977) 1.86
Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem (1991) 1.81
Exosite-driven substrate specificity and function in coagulation. J Thromb Haemost (2005) 1.81
Allostery in disease and in drug discovery. Cell (2013) 1.77
Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood (2008) 1.64
Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood (2008) 1.57
Inhibition of factor XIa as a new approach to anticoagulation. Arterioscler Thromb Vasc Biol (2010) 1.52
FXI is essential for thrombus formation following FeCl3-induced injury of the carotid artery in the mouse. Thromb Haemost (2002) 1.49
Factor XI deficiency in humans. J Thromb Haemost (2009) 1.48
Polyphosphate: an ancient molecule that links platelets, coagulation, and inflammation. Blood (2012) 1.46
Structure and function of factor XI. Blood (2010) 1.37
Mechanism of heparin activation of antithrombin. Role of individual residues of the pentasaccharide activating sequence in the recognition of native and activated states of antithrombin. J Biol Chem (1998) 1.34
Factor XI deficiency. Haemophilia (2008) 1.28
Interaction of designed sulfated flavanoids with antithrombin: lessons on the design of organic activators. J Med Chem (2002) 1.13
Neutralization of low molecular weight heparin by polybrene prevents thromboxane release and severe pulmonary hypertension in awake sheep. Circulation (1990) 1.12
Allosteric regulation of proteases. Chembiochem (2008) 1.11
Identification of a binding site for glycoprotein Ibalpha in the Apple 3 domain of factor XI. J Biol Chem (2004) 1.10
Thrombin activates factor XI on activated platelets in the absence of factor XII. Arterioscler Thromb Vasc Biol (1999) 1.10
Phosphoramidate end labeling of inorganic polyphosphates: facile manipulation of polyphosphate for investigating and modulating its biological activities. Biochemistry (2010) 1.08
Molecular modeling of the prekallikrein structure provides insights into high-molecular-weight kininogen binding and zymogen activation. J Thromb Haemost (2007) 1.06
Coagulation factor XI as a novel target for antithrombotic treatment. J Thromb Haemost (2010) 1.04
Interaction of antithrombin with sulfated, low molecular weight lignins: opportunities for potent, selective modulation of antithrombin function. J Biol Chem (2009) 1.04
Emergency management of bleeding associated with old and new oral anticoagulants. Clin Cardiol (2012) 1.03
Sulfated pentagalloylglucoside is a potent, allosteric, and selective inhibitor of factor XIa. J Med Chem (2013) 0.97
Characterization of a heparin binding site on the heavy chain of factor XI. J Biol Chem (1998) 0.96
A binding site for heparin in the apple 3 domain of factor XI. J Biol Chem (1998) 0.96
Interaction of thrombin with sucrose octasulfate. Biochemistry (2011) 0.95
Structural and functional features of factor XI. J Thromb Haemost (2009) 0.93
Factor XI interacts with the leucine-rich repeats of glycoprotein Ibalpha on the activated platelet. J Biol Chem (2004) 0.93
Diversity of allosteric regulation in proteases. ACS Chem Biol (2012) 0.92
Elevated levels of Factor XI are associated with cardiovascular disease in women. Thromb Res (2002) 0.92
The dimeric structure of factor XI and zymogen activation. Blood (2013) 0.92
Sulfated, low molecular weight lignins inhibit a select group of heparin-binding serine proteases. Biochem Biophys Res Commun (2011) 0.91
Discovery of allosteric modulators of factor XIa by targeting hydrophobic domains adjacent to its heparin-binding site. J Med Chem (2013) 0.90
Factor XI anion-binding sites are required for productive interactions with polyphosphate. J Thromb Haemost (2013) 0.90
Biology of Factor XIII and clinical manifestations of Factor XIII deficiency. Transfusion (2012) 0.90
Factor XI Deficiency. Semin Thromb Hemost (2009) 0.89
A catalytic domain exosite (Cys527-Cys542) in factor XIa mediates binding to a site on activated platelets. Biochemistry (2007) 0.87
Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients. Blood (1994) 0.85
Heparin cofactor II. Adv Exp Med Biol (1997) 0.84
Management of bleeding and reversal strategies for oral anticoagulants: clinical practice considerations. Am J Health Syst Pharm (2013) 0.84
Novel thrombin and factor Xa inhibitors: challenges to reversal of their anticoagulation effects. Curr Opin Hematol (2013) 0.83
Factor XI binding to the platelet glycoprotein Ib-IX-V complex promotes factor XI activation by thrombin. J Biol Chem (2001) 0.83
A rapid transglutaminase assay for high-throughput screening applications. J Biomol Screen (2006) 0.82
Designing allosteric inhibitors of factor XIa. Lessons from the interactions of sulfated pentagalloylglucopyranosides. J Med Chem (2014) 0.81
Factor XI binding to activated platelets is mediated by residues R(250), K(255), F(260), and Q(263) within the apple 3 domain. Biochemistry (2000) 0.79
Plasma factor XIII: understanding the 99%. Blood (2014) 0.78
Identification of novel small molecule inhibitors of activated protein C. Thromb Res (2014) 0.78
Practice guidelines for reversal of new and old anticoagulants. Dis Mon (2012) 0.77